FORM 4

Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See	STATEMENT OF CH
obligations may continue. See	

## ANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Mulligan Seamus						2. Issuer Name <b>and</b> Ticker or Trading Symbol  Jazz Pharmaceuticals plc [ JAZZ ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Munigan Seamus</u>											•			X	Direc	tor		10% O	wner	
(Last)	(Fir	st) (M	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/29/2021										Officer (give title below)			Other (speci below)		
WATERLOO RD						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)														X	X Form filed by One Reporting Person					
DUBLIN	I 4 L2														Form filed by More than One Reporting Person					
(City)	(Sta	ate) (Z	Zip)																	
		Table	I - Non	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	oosed of	, or E	3enef	iciall	y Own	ed				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Exed if an	Deemed ecution Date, ny onth/Day/Year)				Disposed	ies Acquired (A Of (D) (Instr. 3		4 and Securit		ies cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
					Code	v	Amount	(A) (D)	or P	rice	Transa	ction(s) 3 and 4)			(Instr. 4)					
Ordinary Shares 07/29/					/2021				A <sup>(1)</sup>		2,246	I	A \$0.0		1,157,739		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		on Date,	4. Transaction Code (Instr. 8)		5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	rative rities ired r osed )	6. Date   Expirati (Month/	on Da	e Am Sec Und Der Sec		Amount of Securities		Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y D o (I	0. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amou or Numb of Share	er						

## **Explanation of Responses:**

1. These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 29, 2022.

By: /s/Adam Guttmann, as attorney in fact For: Seamus

08/02/2021

Mulligan

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.